Market News AIOpen the app

Allarity Therapeutics is adding three groups of ovarian cancer patients to its Phase 2 trial for stenoparib.

TrialRead the original at pluang.com
Good for ALLR

Allarity is adding 3 ovarian cancer groups to stenoparib testing, widening its development opportunity. Earlier results showed lasting benefits and improved survival, but the added groups have no reported results yet.

ALLR · Allarity Therapeutics

AI read · Good for ALLR

The AI's read

This gives stenoparib more patient groups to be tested in and may widen its development path. Earlier results were described as showing lasting benefits and improved survival. No results from the added groups are reported, so the promise still depends on testing.

Get alerts for ALLR

Follow Allarity Therapeutics (ALLR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALLR
Free on the App Store and Google Play, or on the web.